在PTCA期间预调节对肌激酶释放的有益影响
1Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. wlaskey@medicine.ab.umd.edu
皮肤透光冠状动脉血管造形术 (PTCA) 期间的缺血预调显著减少心肌亡,由较低的肌酸酶 (CK) 水平表明. 这一发现支持了在接受PTCA的高风险患者中预调的临床相关性.
科学领域:
- 心脏病学 心脏病学
- 心血管研究研究心血管研究
- 缺血性心脏病是一种心脏病.
背景情况:
- 之前的研究表明,缺血预调可以减少PTCA期间的功能障碍.
- 这些发现在人类中的临床相关性仍然不清楚.
- 这项研究调查了PTCA介导的预调节是否可以减少心肌缩.
研究的目的:
- 测试是否进行皮肤透光冠状动脉血管造形术 (PTCA) 以引起缺血预先调节可减少心肌缩.
- 通过测量术后肌酸酶 (CK) 水平来评估心肌亡.
主要方法:
- 150名患有不稳定性缺血综合征的患者接受PTCA随机分类.
- 患者接受了经过验证的PTCA介导预条件 (PC) 协议或不受限制的方法 (UC).
- 治疗后8,12小时和24小时测量了肌酸激酶 (CK) 水平.
主要成果:
- 预条件 (PC) 和不受限制的对照 (UC) 组之间的临床成功率相似.
- 肌酸激酶 (CK) 升高的频率在PC组 (7.1%) 与UC组 (25%) 相比显著较低.
- 多变量分析证实,预条件显著减少了CK的释放.
结论:
- 在PTCA期间引发缺血预条件的标准化协议显著降低了肌酸激酶 (CK) 的升高.
- 这些结果表明,在人类中缺血预先调节的临床相关性.
- 在接受PTCA的高风险患者群体中,预约治疗有效降低心肌亡.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
